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A B S T R A C T   
A cell-surface heparan proteoglycan called Syndecan-1 (SDC-1) has multiple roles in healthy and pathogenic 
conditions, including respiratory viral infection. In this study, we explore the dynamic alternation in the levels of 
SDC-1 in cases with COVID-19. A total of 120 cases definitely diagnosed with COVID-19 were admitted to the 
Firoozgar Hospital, Tehran, Iran, from December 1, 2020, to January 29, 2021, and included in our study. Also, 
58 healthy subjects (HS) were chosen as the control group. Patients were classified into two groups: 1) ICU 
patients and (63 cases) 2) non-ICU patients (57 cases). The dynamic changes of serum SCD-1, CRP, IL-6, IL-10, IL- 
18, and Vit D levels a well as the disease activity were investigated in three-time points (T1-T3). Our results 
indicated that the COVID-19 patients had significantly increased SCD-1, CRP, IL-6, IL-10, and IL-18 levels than in 
HS, while the Vit D levels in COVID-19 patients were significantly lower than HS. Further analysis demonstrated 
that the SCD-1, CRP, IL-6, IL-10, and IL-18 levels in ICU patients were significantly higher than in non-ICU 
patients. Tracking dynamic changes in the above markers indicated that on the day of admission, the SCD-1, 
CRP, IL-6, IL-10, and IL-18 levels were gradually increased on day 5 (T2) and then gradually decreased on 
day 10 (T3). ROC curve analysis suggests that markers mentioned above, SDC-1, IL-6, and IL-18 are valuable 
indicators in evaluating the activity of COVID-19. All in all, it seems that the serum SDC-1 levels alone or 
combined with other markers might be a good candidate for disease activity monitoring.   
1. Introduction 
Type I transmembrane heparan sulfate proteoglycans are called 
syndecans (SDCs) that can communicate with many ligands, such as 
chemokines, adhesion receptors, proteinases, and cytokines [1]. After 
the interaction between SDCs and their ligands, SDCs launch several 
biological signaling experiences connected to inflammation, angiogen-
esis cell adhesion, and tissue restoration [2–6]. The human genome 
encodes four syndecans, including SDC-1,-2, -3, and -4. SDCs in normal 
conditions support cell homeostasis and manage inflammatory reactions 
throughout trauma and infection [7]. The recent finding from studies 
performed on animal models of various diseases has rendered definite 
evidence that SDC-1 plays a crucial function in promoting inflammatory 
conditions, tumors, and infectious disease. These SDC-1 functions are 
critical in the pathophysiology of infectious diseases provided by studies 
using animal and cell culture-based infection models. It was observed 
that the loss or decline of SDC-1 enables mice or cells to resist infection 
by several viral and bacterial pathogens significantly [8–11]. The un-
derlying molecular mechanisms have yet to be accurately determined. 
However, numerous investigations have exhibited impressive features of 
how both cell surface and shed SDC-1 can increase pathogenesis by 
different molecular mechanisms [12]. Recently, humanity experience a 
* Corresponding authors at: Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran. 
E-mail addresses: karampour.s@iums.ac.ir (S. Karampoor), keyvani.h@iums.ac.ir (H. Keyvani).  
Contents lists available at ScienceDirect 
International Immunopharmacology 
journal homepage: www.elsevier.com/locate/intimp 
https://doi.org/10.1016/j.intimp.2021.107684 
Received 18 March 2021; Received in revised form 13 April 2021; Accepted 13 April 2021   
International Immunopharmacology 97 (2021) 107684
2
new destructive viral pandemic after the pandemic flu (N5N1) in 1918; a 
novel coronavirus called severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) caused horrifying disease accompanied by high mor-
tality, economic, and health burden on the world community [13,14]. 
The disease caused by the SARS-CoV-2 was called COVID-19, which 
originated from Wuhan, Hubei province, China, and then expanded 
worldwide [15–18]. In addition to acute respiratory failure, the SARS- 
CoV-2 can damage other organs, which progresses rapidly and eventu-
ally drives to multiple organ collapse and death [19,20]. The early 
diagnosis of COVID-19 is problematic, given that some patients do not 
have any specific signs/symptoms, or specific radiological abnormal-
ities, in the early stages. Therefore, some investigation highlights that 
the early stages’ immediate identification in the early stages can be 
necessary to halt the disease’s spread and establish an effective treat-
ment plan [21,22]. In the previous study, several inflammatory factors, 
including white blood cells (WBC), platelet (PLT), CRP, lymphocyte (L), 
serum amyloid A (SAA), and procalcitonin (PCT) have been employed in 
the clinic as inflammation indicators [23]. Also, recently the Fraser et al. 
[24] and Suzuki et al. [25] investigate the possible role of SDC-1 in 
COVID-19 pathogenesis. Hence, we aimed to validate previous work 
[24–26] with a larger patient cohort and with graded severity in the 
present investigation. In summary, in the present work, we explore the 
dynamic changes in the levels of selected factors, including SDC1, CRP, 
IL-6, IL-18, IL-10, and vitamin D in the serum of patients with COVID-19, 
to help estimate the disease severity and management of COVID-19 
diseases. 
2. Material and methods 
A comparative cross-sectional study was intended to understand the 
dynamic changes of the SDC-1 alone or combined with some factors 
include IL-6, IL-10, IL-18, CRP, and Vit D associated with the severity of 
COVID-19 patients admitted to the Firouzgar Hospital, Tehran, Iran. In 
order to catch legal and ethical authority for collecting the specimens, 
informed consent was obtained from all individuals who engaged in this 
study. Additionally, this research was authorized by the ethics com-
mittee of Iran University of Medical Sciences (IUMS) (ECIUMS; IR.IUMS. 
FMD.REC.1399.624). A total number of 120 patients with COVID-19 
admitted to the Firouzgar Hospital, IUMS were recruited in this inves-
tigation and classified into two groups according to the Li et al. criteria 
as follows: the first group comprised 63 cases with COVID-19 (severe 
patients hospitalized in ICU), the second group consisted of 57 patients 
with COVID-19 (moderate patients). Also, in this study, 58 healthy 
subjects enrolled as the control group. We three times 5 ml peripheral 
blood take and collected from each patient, and quickly following 
sample gathering, the serum was isolated by centrifugation and put at 
− 70 ◦C up to use. 
2.1. Laboratory validation and treatment 
The real-time polymerase chain reaction was used to detect and 
confirm SARS-CoV-2 infection within three hours after sample collection 
(sputum and throat swab specimens). Serum biochemistry and blood 
count were done on the day of admission. According to the COVID-19 
Diagnosis and Treatment Plan declared by the National Health Com-
mittee of Iran, patients underwent supportive oxygen treatment, anti-
viral prescription, and other supportive therapies. 
2.2. ELISA for SDC-1, IL-16, IL-10, IL-18, and CRP 
For determining the serum levels of SDC-1, IL-6, IL-10, IL-18 (Abcam, 
Cambridge, MA, USA), and CRPBOSTER BIOLOGICAL TECHNOLOGY, 
EK7040), we used enzyme-linked immunosorbent assay (ELISA) kits 
following the manufacturer’s instructions. We used a quantitative 
chemiluminescent immunometric assay for assessing Vit D levels in 
serum (DiaSorin, spA, Via Crescentino, Vercelli, Italy). All specimens 
were tested in duplicate, and the mean values of individual sera were 
employed for the statistical interpretation. The intra-assay and inter-
assay coefficients of variation (CV) were b12.0% for all calculated 
agents [27]. 
2.3. Statistical methods 
Continuous and categorical variables were displayed as median 
(IQR) and n (%), sequentially. We applied the Wilcoxon rank-sum test, 
χ2 test, or Fisher’s exact test where appropriate to analyze differences 
among different groups. The relationship between laboratory tests was 
analyzed using the Pearson correlation coefficient. The Receiver Oper-
ating Characteristic curve (ROC curve) was employed to determine the 
area under the curve (AUC) of SDC-1, IL-6, IL-18, IL-10, CRP, and Vit D 
meant to assess the sensitivity and specificity of these markers. A two- 
sided α of less than 0⋅05 was regarded statistically significant. Statisti-
cal analyses were done using R version 4.0.3 (2020-10-10). 
Table 1-1 
Demographic and clinical parameters of patients with COVID-19.    
Group  





N = 57 
p- 
valueb 
Sex 120    0.092 
Female  56 (47%) 34 (54%) 22 (39%)  
Male  64 (53%) 29 (46%) 35 (61%)  
Age 120 57 (38, 70) 61 (47, 74) 52 (36, 68) 0.050 
ESR 120 44 (28, 56) 43 (26, 56) 45 (30, 56) 0.9 














M.C.V 120 88 (85, 92) 88 (85, 91) 88 (84, 93) > 0.9 
Hct 120 40 (34, 44) 40 (35, 43) 40 (32, 44) 0.4 





























SGPT 120 21 (15, 34) 24 (16, 36) 18 (15, 31) 0.075 
SGOT 120 25 (19, 44) 30 (22, 46) 23 (16, 30) 0.017 
Cigarette 120    0.6 
Negative  101 (84%) 52 (83%) 49 (86%)  
Positive  19 (16%) 11 (17%) 8 (14%)  
Opium 120    0.048 
Negative  116 (97%) 63 (100%) 53 (93%)  
Positive  4 (3.3%) 0 (0%) 4 (7.0%)  
Alcoholic_drinks 120   >0.9  
Lung_disease 120   0.4  
Negative  115 (96%) 60 (95%) 55 (96%)  
Positive  5 (4.2%) 3 (4.8%) 2 (3.5%)  
Kidney_failure 120    0.044 
Negative  101 (84%) 49 (78%) 52 (91%)  
Positive  19 (16%) 14 (22%) 5 (8.8%)  
Dialysis 120    >0.9 
Negative  110 (92%) 58 (92%) 52 (91%)  
Positive  10 (8.3%) 5 (7.9%) 5 (8.8%)  
Heart_disease 120    >0.9 
Negative  97 (81%) 51 (81%) 46 (81%)  
Positive  23 (19%) 12 (19%) 11 (19%)  
Death 120    0.001 
Negative  110 (92%) 53 (84%) 57 (100%)  
Positive  10 (8.3%) 10 (16%) 0 (0%)  
CT.value 120 25 (24, 33) 25 (24, 33) 27 (23, 33) 0.7  
a n (%); Median (IQR). 
b Pearson’s Chi-squared test; Wilcoxon rank sum test; Fisher’s exact test. 
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3. Results 
3.1. Demographic characteristics 
As presented in Tables 1-1 and 1-2, all individuals, including ICU 
patients, non-ICU patients, and HS, were equivalent in terms of sex and 
age as there were no meaningful differences between them (P < 0.05). 
Also, Table 1 has illustrated that the laboratory findings and some risk 
factors such as smoking, kidney failure, lung disease, and others. As 
shown in Table 2, ICU patients’ death rate had significantly higher than 
non- ICU patients (P < 0.05). Also, the death event was positively 
associated with older age (P < 0.001). Besides, in Table 2, we illustrated 
the difference among laboratory findings and some mentioned risk 
factors between ICU and non-ICU patients. As presented in Table 1, the 
lactate dehydrogenase (LDH), hemoglobin (Hb), glutamic-oxaloacetic 
transaminase (SGOT), death rate, Kidney failure in ICU patients were 
significantly higher than in non-ICU patients (P < 0.05). As demon-
strated in Table 2, further analysis showed that some parameters such as 
age, lung disease, and heart disease were significantly higher in dead 
patients than in alive patients (P < 0.05). 
Table 1-2 
The age and sex characteristics of COVID-19 cases and healthy subjects.  









N = 57a 
Sex 176     0.045 
Female  74 (42%) 18 (32%) 34 
(54%) 
22 (39%)  
Male  102 (58%) 38 (68%) 29 
(46%) 
35 (61%)  





a n (%); Median (IQR). 
b Pearson’s Chi-squared test; Kruskal-Wallis rank sum test. 
Table 2 
Difference between demographic characteristics and laboratory findings be-
tween ICU patients and non-ICU patients.     
Group  








Group 120   Death 0.001 
ICU  63 (52%) 53 (48%) 10 (100%)  
Non ICU  57 (48%) 57 (52%) 0 (0%)  
Sex 120    0.7 
Female  56 (47%) 52 (47%) 4 (40%)  
Male  64 (53%) 58 (53%) 6 (60%)  
Age 120 57 (38, 70) 54 (37, 67) 80 (76, 84) <0.001 
ESR 120 44 (28, 56) 45 (27, 56) 38 (34, 58) 0.8 














M.C.V 120 88 (85, 92) 88 (85, 92) 87 (85, 89) 0.6 
Hct 120 40 (34, 44) 40 (34, 44) 41 (37, 48) 0.2 

















W.B.C 120 6.1 (5.0, 
9.2) 
6.0 (5.0, 9.1) 7.4 (5.0, 
9.2) 
0.7 







SGPT 120 21 (15, 34) 21 (15, 34) 22 (15, 38) 0.6 
SGOT 120 25 (19, 44) 25 (18, 43) 24 (22, 71) 0.6 
Cigarette 120    0.7 
Negative  101 (84%) 93 (85%) 8 (80%)  
Positive  19 (16%) 17 (15%) 2 (20%)  
Opium 120    >0.9 
Negative  116 (97%) 106 (96%) 10 (100%)  
Positive  4 (3.3%) 4 (3.6%) 0 (0%)  
Alcoholic_drinks 120    >0.9 
Negative  115 (96%) 105 (95%) 10 (100%)  
Positive  5 (4.2%) 5 (4.5%) 0 (0%)  
Kidney_failure 120    0.7 
Negative  101 (84%) 93 (85%) 8 (80%)  
Positive  19 (16%) 17 (15%) 2 (20%)  
Dialysis 120    0.2 
Negative  110 (92%) 102 (93%) 8 (80%)  
Lung_disease 120    0.042 
Negative  102 (85%) 96 (87%) 6 (60%)  
Positive  18 (15%) 14 (13%) 4 (40%)  
Heart_disease 120    0.022 
Negative  97 (81%) 92 (84%) 5 (50%)  
Positive  23 (19%) 18 (16%) 5 (50%)  
CT.value 120 25 (24, 33) 26 (24, 33) 24 (22, 34) 0.7  
a n (%); Median (IQR). 
b Fisher’s exact test; Wilcoxon rank sum test. 
Table 3 
The dynamic changes in the CRP, IL-6, IL-10, 1L-18, SDC-1, and Vitamin D levels 
among patients with COVID-19 and Healthy subjects.     
Group  







N = 57a 
p- 
valueb 




















IL6_T2 176 88 (27, 
115) 










IL18_T1 176 140 (43, 
168) 







IL18_T2 176 190 (45, 
267) 







IL18_T3 176 90 (40, 
113) 





















IL10_T1 176 4 (3, 6) 3 (2, 4) 5 (4, 8) 4 (3, 5) <0.001 
IL10_T2 176 8 (5, 13) 4 (3, 5) 18 (11, 
24) 
8 (6, 10) <0.001 
IL10_T3 176 6 (5, 9) 5 (4, 6) 11 (8, 
15) 
6 (5, 7) <0.001 
Syndecan_T1 
176 



















a Median (IQR). 
b Kruskal-Wallis rank sum test. 
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3.2. The test results of the assessment of CRP, IL-6, IL-10, 1L-18, SDC-1, 
and Vitamin D levels in patients with COVID-19 
The relationship between CRP, IL-6, IL-10, 1L-18, SDC-1, and Vit D 
levels, were shown in Table 3 and Fig. 1. According to Table 3 and Fig. 1, 
the levels of the above markers were significantly elevated in patients 
with COVID-19 than HS. Also, the CRP, IL-6, IL-10, 1L-18, SDC-1 levels 
in ICU patients were significantly higher than non-ICU patients (P <
0.001). Our result indicated that Vit D levels in COVID-19 significantly 
lower than in healthy subjects (P < 0.001). Further analysis shows that 
the Vit D levels had significantly lower in ICU patients when compared 
with non-ICU patients (P < 0.05). Also, our results indicated that with 
disease progression, the levels of CRP, IL-6, IL-10, 1L-18, SDC-1 gradu-
ally increase from the day of admission to day five and then decreased 
gradually on day 10 after hospitalization (Table 3 and Fig. 1). Concur-
rently, the Vit D levels from day of admission to day ten gradually 
Fig. 1. The dynamic changes in the concentration of CRP, IL-6, IL-10, 1L-18, SDC-1, and Vitamin D from day 0 or T1 (hospitalization), day five after hospitalization 
or T2, and day ten after hospitalization or T3 in ICU, non-ICU, and healthy subjects. 
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decreased (P < 0.05). 
3.3. Comparison of dynamic changes in the levels of CRP, IL-6, IL-10, 1L- 
18, SDC-1, and Vitamin D between ICU and non-ICU patients 
The CRP levels were significantly higher in ICU patients than those of 
non-ICU patients at the time of hospitalization (P < 0.001); however, the 
CRP levels gradually decreased from the day of admission to day ten. 
Other markers, including IL-6, IL-10, 1L-18, and SDC-1 levels, were 
significantly higher in ICU patients than those of non-ICU patients (P <
0.001). Also, the levels of these markers in both groups gradually in-
crease from the day of hospitalization to day five and gradually decrease 
to day ten. Our result indicated that the levels of Vit D levels were 
significantly lower in ICU patients than non-ICU patients (P < 0.001). 
Concurrently, the Vit D levels gradually increased in both groups from 
the day of admission to day ten (Table 3) (Fig. 1). 
3.4. The comparison of the dynamic changes in the levels of CRP, IL-6, IL- 
10, 1L-18, SDC-1, and Vitamin D among death patients and alive patients 
Our result indicated that the dead cases had significantly higher 
levels of CRP, IL-6, IL-10, 1L-18, and SDC-1 than in alive cases (P <
0.001) (Table 4) (Fig. 2). The Vit D levels in death cases were signifi-
cantly lower than those of alive cases (P < 0.001). Further analysis 
showed that CRP, IL-6, IL-10, 1L-18, and SDC-1 levels at the three-time 
points in death cases were significantly higher than those alive (P <
0.001). While concurrently, our analysis demonstrated that the Vit D 
levels in three-time point significantly lower in death cases when 
compared to the alive cases (P < 0.001). Besides, more interpretation 
indicated that there was no relation between SDC-1, IL-6, IL-10, IL-18, 
CRP, and Vit D levels and cycle threshold (Fig. 3) (P > 0.05). 
3.5. The value of SDC-1 on 1th day of admission compared with other 
indexes on the 1st for prognosis judgment of patients with COVID‑19 
ROC curve analysis demonstrated that the SDC-1 and other indexes 
such IL-6, IL-10, IL-18, CRP, and Vit D were significantly different be-
tween COVID-19 cases and HS. Also, According to the ROC curve 
analysis results, the areas under the curve (AUC) of SDC-1 on the 1th and 
IL-6, IL-10, IL-18, CRP, and Vit D on the 1st day were 0.7054, 0.8794, 
0.6792, 0.8932, 0.664, and 0.6145, respectively (Fig. 4). In sum, the 
ROC result indicated that the SDC-1 alone or coupled with IL-6 and IL-18 
might be a good candidate for monitoring disease activity. 
4. Discussion 
The novel pandemic infectious disease is called COVID-19 is a highly 
transmissible virus accompanied by high mortality and endangers 
human well-being and public safety [13,15,28–30]. Many investigations 
are launched for unraveling the pathogenesis mechanism of SARS-CoV- 
2. The previous studies demonstrated that RNA viruses such as hepatitis 
E virus [8], human papillomavirus [31], human immunodeficiency virus 
[32–34] for the attach to target cells use an SDC-1 on the cell surface and 
another viral pathogen for their attachment and establish infection have 
also been shown to bind to HSPGs on the cell surface [35,36]. The recent 
investigation has provided further support for the performance of SDC-1 
in the pathophysiology of viral infection; in this study, Bermejo- 
Jambrina et al. show that for SARS-CoV-2 infection in permissive 
cells, the cell surface HSPG, including SDC-1 and -4, are needed, and also 
in alveolar macrophages, the established infection by SARS-CoV-2 effi-
ciently hindered via low molecular weight heparins (LMWH) [37]. 
Given the dilemma role of SDC-1 during the progression of inflammatory 
disease such as respiratory viral infection, in the current research, we 
explore and monitoring the dynamic alterations in the SDC-1 concen-
tration along with some markers, including IL-6, IL-10, IL-18, CRP, and 
Vit D in cases with COVID-19. 
Several inflammatory indexes are commonly employed to prognos-
ticate, diagnose, and estimate many inflammatory conditions, including 
COVID-19, platelet count, procalcitonin, white blood count, CRP, SAA 
lymphocyte [23,25]. The present result indicated that the levels of SDC- 
1 in cases with COVID-19 had significantly higher than healthy in-
dividuals. Also, we showed that the serum SDC-1 levels were signifi-
cantly higher in ICU patients when compared with non-ICU patients. 
The levels of SDC gradually increased and then gradually decreased with 
disease duration. From day 0 (day of hospitalization) to day 5 (5 days 
after hospitalization), the levels of SDC-1 increased. However, from day 
5 to day ten, the levels of SDC-1 gradually decreased in ICU and non-ICU 
patients. The complicated structure is called the glycocalyx, composed 
of proteoglycans (such as SDC-1), glycosaminoglycans, and numerous 
plasma proteins [38]. The glycocalyx is a crucial regulator of endothelial 
cell homeostasis, inflammatory processes, and tissue edema [39]. It 
consists of membrane-bound proteoglycans and glycoproteins and 
covers endothelial cells at the luminal vessel side [39,40]. This weak 
boundary is interrupted in inflammatory conditions [41] and cardio-
vascular disorders [42,43], is correlated with patient consequences 
[44,45]. Recently, Fraser and colleagues highlight that the cases with 
COVID-19 had higher levels of SDC-1, P-selectin, and hyaluronic acid as 
glycocalyx-degradation products [24]. Also, Fraser and colleagues, ac-
cording to the previous investigation, proposed that the glycocalyx- 
degradation may underlie platelet adhesion and thrombosis risk in 
COVID-19 patients [24]. In this way, according to Fraser et al. [25] and 
Suzuki et al. [37], our result highlighted that the levels of SDC-1 
elevated in cases with COVID-19. 
On the other hand, during infectious disease, SDC-1 obviously en-
hances the pathogenesis of some pathogens. It propitiates the binding 
and entrance of pathogens into host cells and represses host protection 
mechanisms. Besides, the lack of SDC-1 is a gain of function mutation 
that boosts the immunity of mice to various bacterial diseases. These 
Table 4 
The association between dynamic changes in the serum levels of CRP, IL-6, IL- 
10, 1L-18, SDC-1, and Vitamin D with death in patients with COVID-19.     
Death  








CRP_T1 120 98 (84, 124) 92 (82, 120) 202 (189, 
225) 
<0.001 
CRP_T2 120 42 (34, 48) 42 (33, 46) 143 (126, 
145) 
<0.001 
CRP_T3 120 21 (17, 26) 21 (17, 24) 70 (59, 78) <0.001 
IL6_T1 120 76 (65, 100) 74 (64, 90) 210 (192, 
264) 
<0.001 
IL6_T2 120 102 (88, 134) 100 (87, 123) 204 (190, 
252) 
<0.001 
IL6_T3 120 38 (32, 46) 37 (32, 44) 274 (247, 
321) 
<0.001 
IL18_T1 120 158 (140, 
187) 
156 (139, 174) 349 (342, 
359) 
<0.001 
IL18_T2 120 230 (189, 
284) 
221 (187, 278) 489 (465, 
536) 
<0.001 
IL18_T3 120 108 (90, 122) 102 (90, 116) 206 (197, 
234) 
<0.001 
VitD_T1 120 18 (13, 21) 18 (14, 23) 10 (8, 12) <0.001 
VitD_T2 120 19 (15, 21) 19 (16, 22) 12 (8, 15) <0.001 
VitD_T3 120 21 (16, 22) 21 (17, 23) 14 (7, 16) <0.001 
IL10_T1 120 5 (4, 6) 5 (4, 6) 22 (10, 24) <0.001 
IL10_T2 120 10 (7, 19) 10 (7, 17) 48 (29, 55) <0.001 
IL10_T3 120 8 (6, 12) 8 (6, 11) 22 (11, 27) 0.001 
Syndecan_T1 
120 
73 (63, 81) 71 (62, 79) 116 (85, 127) <0.001 
Syndecan_T2 
120 





61 (53, 69) 61 (52, 67) 85 (77, 91) <0.001  
a Median (IQR). 
b Wilcoxon rank sum test. 
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findings recommend that one of the critical roles of mammalian SDC-1 
in vivo is to guarantee the sufficient and accurate operative of inflam-
mation [12]. Nevertheless, this beneficial role of SDC-1 arrives at a value 
as particular microbial pathogens, and tumor cells have both accom-
modated or emerged to catch the benefit of SDC-1 for their pathophys-
iology. Since various pathogens attach to HSPGs on the cell surface for 
their binding and entrance, it is unknown how? Soluble SDC-1 is not a 
host protection mechanism that immediately decreases microbial 
binding places. One possible explanation is that only highly efficient 
pathogens that hold excess mechanisms for binding, including some 
bacterial pathogen, including Staphylococcus aureus (S. aureus), can 
utilize soluble SDC-1 to support their pathophysiology [46]. Another 
Fig. 2. The comparison between dynamic changes in the CRP, IL-6, IL-10, 1L-18, SDC-1, and Vitamin D levels from three-time points (T1-T3) between alive 
(recovered) and dead patients. 
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possible reason is that some pathogens may employ both forms of SDC-1 
(cell surfaces and shed SDC-1) to bind to host cells and hinder host 
immunity, whether SARS-CoV-2 like S. aureus hold the capability to 
provoke SDC-1 shedding to the increase of the production of SDC-1 to 
support their pathophysiology remains to be discovered. 
The vast majority of finding from the latest research has highlighted 
that inflammation represents an axial function in the pathogenesis of 
COVID-19 [47–50]. Our work’s data show that the levels of inflamma-
tory indexes, such as IL-6, IL-18, and CRP, were significantly elevated in 
cases with COVID-19 than in HS. Further analysis revealed that the 
levels of these inflammatory markers in ICU patients were significantly 
higher than in non-ICU patients. We have also indicated that the IL-6 and 
IL-18 levels gradually increased from day 0 to day 5 in both ICU and non- 
ICU patients. However, the CRP levels gradually decreased from day 0 to 
Fig. 3. The correlation between CRP, IL-6, IL-10, IL-18, SDC-1, and Vitamin D with the cycle threshold (Ct) value at day of hospitalization.  
Fig. 4. ROC curve analysis between, A: Healthy people vs. ICU patients, B: Healthy people vs. Non-ICU patients, and C: Non-ICU patients vs. ICU patients. AUC: Area 
under the curve. 
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day 10 in both groups of patients. Our result in agreement with the 
studies shows that the IL-6 [26,51–57], IL-18 [26,58–60], and CRP 
elevated in patients with COVID-19 [61–63]. Besides, our data demon-
strated that the IL-10 levels were significantly higher in cases with 
COVID-19 than in HS. 
Further analysis of our data indicated that the levels of IL10 were 
significantly higher in ICU patients than non-ICU patients. Our result 
agreed with several investigations that revealed the levels of IL-10 
elevated in patients with COVID-19 [52,64–66]. Also, dead patients 
significantly had higher IL-6, IL10, IL-18, and CRP levels than alive 
patients. The current evidence reflected that the inflammatory response 
might the tries of the immune system for the control of SARS-CoV-2 
infection; however, the recent investigations showed that the SARS- 
CoV-2 could induce inflammation, necroptosis, and apoptosis in a 
mouse model infected with SARS-CoV-2 and lung sections of postmor-
tem of fatal COVID-19 cases [67]. Also, the raised IL-10 levels in patients 
with COVID-19 may reflect the immune system’s compensatory function 
to alleviate inflammation induced by SARS-CoV-2 [65]; nevertheless, a 
growing body of clinical data implies that dramatic early height of IL-10 
levels may perform a pathological performance in the severity of COVID- 
19 pathogenesis [65]. As results showed, the levels of SDC-1 positively 
correlated with anti- and pro-inflammatory markers, including IL-6, IL- 
18, CRP, and IL-10, which one explanation is SDC-1 may act as a 
compensatory response for the alleviation of inflammatory response 
were provoked by SARS-CoV-2. In contrast, as mentioned before, 
another finding highlights that the soluble SDC-1 in the context of in-
fectious disease has propathogenic functions to promote infection [12]. 
So, it is possible that the SARS-CoV-2 may subvert the production of 
SDC-1 for their advantage and promote the pathogenesis. 
The vast majority of observational investigations have highlighted a 
low vitamin D status is correlated with a high experience of viral 
infection (respiratory viral infections), which globally display signifi-
cant wellness and economic burdens [68–71]. Our findings showed that 
the Vit D levels were significantly lower in COVID-19 cases than in HS. 
Also, our data revealed that the ICU patients significantly had lower 
levels of Vit D compared to non-ICU patients. Besides, the concentration 
of Vit D gradually decreased in both ICU and non-ICU patients from day 
0 to day 10. Our result agreed with the studies that indicated that the 
COVID-19 patients had lower levels of Vit D [71–75]. As mentioned 
above, data from observational investigations have recommended that 
Vit D supplementation can lessen the odds of promoting respiratory 
diseases, especially in Vit D-deficient groups; however, randomized 
controlled trials (RCTs) have generated mixed outcomes [76]. Despite 
that, recent meta-analysis conclusions designate the inherent capacity of 
vitamin D in improving COVID-19 severity in hospitalized cases [77]; 
more robust data from RCTs are required to confirm its impacts on the 
severity and mortality rate of COVID-19. 
Finally, the ROC curve report reveals that AUC that from high to low 
is: IL-18 > IL-6 > SDC-1 > IL-10 > CRP > Vit D, implying that SDC-1 
along with IL-6 and IL-18 is a reliable indicator in differentiating se-
vere SARS-CoV2 infection (ICU patients) cases from moderate ones 
(non-ICU patients). 
Ultimately, the underlying molecular mechanisms in which SDC-1 
governs in the physiological versus pathological situation remain opa-
que. Future investigations directed at determining the molecular aspects 
of how expression and shedding of SDC-1 are switched on or off and also 
how particular cellular and tissue parts throughout viral pathogenesis 
(such as SARS-CoV-2) are predicted to uncloak innovative therapeutic 
targets for a viral infection such as SARS-CoV-2. 
In summary, Our present findings provide further support for using 
SDC-1 alone or combined with other markers such as IL-6, IL-10, IL-18, 
CRP, and Vit D might be applied as a significant indicator to designate 
and pursue inflammation states in cases with COVID-19. Also, SDC-1 
and the indexes mentioned above are precious indicators in moni-
toring the disease activity of COVID-19. All in all, it seems that the dy-
namic monitoring alternation in the SDC-1 serum levels, coupled with 
some markers including IL-6 and IL-18, could be a valuable approach in 
diagnosing and establish an effective treatment plan in COVID-19 
patients. 
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